Switch to:
More From Other Websites
6:01 pm Sarepta Therapeutics dosed first patient in Ph III trial of SRP-4045 and SRP-4053 for... Sep 28 2016
Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and... Sep 28 2016
Sarepta's Costly Muscular Dystrophy Drug Flirts With Big Pharma M&A Sep 28 2016
Here’s Why These Five Stocks Are Trading Higher Today Sep 28 2016
Selling Into Strength Can Be a Great Strategic Move Sep 28 2016
RBC Capital Markets more than doubles Sarepta price target, citing 'potential for real upside' Sep 28 2016
Sarepta Therapeutics (SRPT) Stock Climbs, Analysts Bullish on Exondys Sep 28 2016
Sarepta: 'Yes, We're Aware Our Price Target is $50 Higher Than the Current Price' Sep 28 2016
Sarepta’s Manufacturing Challenge (SRPT) Sep 27 2016
BioMarin Takes Aim at Rival Sarepta (BMRN, SRPT) Sep 26 2016
Why Wells Fargo, Sarepta, Delphi, UPS, and More Are Making Headlines Sep 26 2016
For Traders, Planning Is More Important Than the Plan Sep 25 2016
[$$] Sarepta Still Has Upside Sep 24 2016
Sarpeta Approval Challenged by FDA (SRPT) Sep 23 2016
Sarpeta Raises Offering After FDA Approval (SRPT) Sep 23 2016
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Sep 23 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK